This site provides information on the EPIC study and details on case recruitment for veterinary professionals worldwide. Pimobendan is a prescription only medicine, licensed for the treatment of congestive heart failure due to mitral valve disease or dilated cardiomyopathy.

The EPIC Trial site is intended for veterinary professionals. By clicking 'Continue' you are affirming that you are a veterinary professional.

Evaluating Pimobendan in Cardiomegaly
Media & Journalists  •  Contact  •  Helpful Links  •  FAQs  •  Site Map

QUEST Revisited

The impetus for EPIC is an earlier study sponsored by Boehringer Ingelheim called QUEST (Quality of Life and Extension of Survival Time). At the time, it was the largest clinical study of its kind conducted among dogs with CHF due to MMVD. This international, multi-center trial compared the effects of two different treatments. QUEST established pimobendan as the reference treatment for dogs with CHF caused by MMVD.

One key question was left unanswered: Can pimobendan also delay the onset of signs of congestive heart failure? EPIC, which is even more comprehensive, will seek the answer.

For more information about QUEST, please visit

Professor Jens Häggström
Swedish University of Agricultural Sciences
Faculty of Veterinary Medicine and Animal Science
Uppsala, Sweden 


Investigator Sign in

Investigators, please sign in here.

Prof. Jens Häggström

An Investigator's Point of View

Prof. Adrian Boswood

An Investigator's Point of View